The patient felt anxious and was concerned in the long run about the safety and what can happen; The patient was vaccinated with the first dose of Imovax, the second, third, and fourth were RabAvert; Case reference number US-BN-2023-000056 is a spontaneous case report initially received on 11-Jan-2023 from a consumer via Communication (reference number: USBAV23-0068) and concerns a female patient *born in 2001.*  *The patient's current condition included anxiety disorder.*  *The patient was not taking any concomitant medications.*  On an unspecified date, the patient had a low exposure to rabies.  *On an unspecified date in Dec-2006, an unknown time after exposure to rabies, the patient was vaccinated with the co-suspect Imovax (batch number: unknown), at an unknown dose, route, or site of administration, for post-exposure immunization to rabies.*  *On unspecified dates, an unknown amount of time after exposure to rabies, the patient was vaccinated with the first dose of RabAvert (batch number: unknown) at an unknown dose, route or site of administration, for post-exposure immunization to rabies (explicitly coded as 'interchange of vaccine products').*  *On unspecified dates, an unknown amount of time after exposure to rabies, the patient was vaccinated with the second dose of RabAvert (batch number: unknown) at an unknown dose, route, or site of administration.*  *On unspecified dates, an unknown amount of time after exposure to rabies, the patient was vaccinated with the third dose of RabAvert (batch number: unknown) at an unknown dose, route, or site of administration.*  On an unspecified date, an unknown amount of time after exposure to rabies, the patient felt anxious and just concerned in the long run about the safety and what could happen, and if could relate it to the vaccine.  *At the time of follow-up report, the outcome of the event 'anxiety' was unknown.*  The reporter assessed the event of 'anxiety' as non-serious and possibly related to RabAvert.  Additional information received on 13-Jan-2023 included local case ID.  All follow-up information is blended into the case narrative above, with the latest information presented between asterisks (*).  Follow-up information received from consumer on 08-Feb-2022. New information included patient's details, details for medical history and concomitant medication, vaccination details for received vaccines, co-suspect vaccine Imovax and updated contact details for the reporter. New event special situation 'interchange of vaccine products' added.; Reporter's Comments: A female patient born in 2001 was vaccinated with Imovax, for post-exposure immunization to rabies. On unspecified dates, the patient received three more doses of RabAvert, which is considered as interchange of vaccine products. On an unspecified date, an unknown amount of time after exposure to rabies, the patient felt anxious. The event of anxiety is unlisted for Rabipur according to the guidelines, whilst interchange of vaccine products is listed per company convention. The patient's current condition included anxiety disorder and the patient was not taking any concomitant medications. Having in mind that the patient had medical history of anxiety disorder and an uncertain temporal relationship, the causality for reported anxiety is assessed as not related to RabAvert. Interchange of vaccine products is not related to RabAvert, but to a human factor. The case is non-serious.; Sender's Comments: A female patient born in 2001 was vaccinated with Imovax, for post-exposure immunization to rabies. On unspecified dates, the patient received three more doses of RabAvert, which is considered as interchange of vaccine products. On an unspecified date, an unknown amount of time after exposure to rabies, the patient felt anxious. The event of anxiety is unlisted for Rabipur according to the guidelines, whilst interchange of vaccine products is listed per company convention. The patient's current condition included anxiety disorder and the patient was not taking any concomitant medications. Having in mind that the patient had medical history of anxiety disorder and an uncertain temporal relationship, the causality for reported anxiety is assessed as not related to RabAvert. Interchange of vaccine products is not related to RabAvert, but to a human factor. The case is non-serious.